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Abstract
Introduction: 99mTc-sestamibi, a radiopharmaceutical widely used in the assessment of myocardial perfusion, can be used as an indicator 
of thyroid disease due to its oncophilic character. The aim of this study was to establish the usefulness of performing additional examina-
tions of radiotracer uptake in the thyroid gland during standard stress scintigraphy with sestamibi in order to identify thyroid diseases.
Material and methods: After a retrospective evaluation of 330 consecutive myocardial perfusion scintigraphies performed in our hospital 
during one year, 41 patients with a focal accumulation of 99mTc-sestamibi in the thyroid were enrolled in the study. The patients underwent 
clinical examinations, including thyroid ultrasonography and TSH, fT4, fT3, aTPO, TRAB, calcitonin, and CEA levels. Based on the thyroid 
ultrasounds, 21 patients were referred for fine-needle aspiration biopsy of the thyroid.
Results: An abnormal accumulation of radiotracer in the thyroid was found in 41(12.4%) of 330 patients who underwent stress cardiac 
scintigraphy. Thirteen (31.7%) of those patients had multinodular euthyroid goitres, 12 (29.2%) had a single thyroid nodule (including 
two autonomous nodules), 11 (26.8%) had autoimmune thyroid disease, and one (2.4%) had papillary thyroid carcinoma. In 12 (29.2%) 
with thyroid tracer uptake there was no thyroid pathology.
Conclusions: 
1. Additional evaluation of radiotracer uptake in the thyroid during standard myocardial perfusion scintigraphy is a valuable tool in the 
detection of thyroid diseases. 
2. The additional or parallel evaluation of radiotracer uptake in the thyroid should be considered during every myocardial scintigraphy. 
(Endokrynol Pol 2015; 66 (6): 521–525)
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Streszczenie 
Wstęp:  99mTc-sestamibi jest  radiofarmaceutykiem stosowanym standardowo między innymi w ocenie perfuzji mięśnia sercowego. Ze 
względu na właściwości onkofilne może być także wykorzystywany w diagnostyce chorób tarczycy. Celem pracy była analiza przydat-
ności dodatkowej oceny gruczołu tarczowego podczas scyntygraficznej próby wysiłkowej z wykorzystaniem sestamibi do wykrywania 
chorób tarczycy.
Materiał i metody: Po ocenie 330 kolejnych badań scyntygrafii perfuzyjnej serca w Zakładzie Medycyny Nuklearnej WIM wykonanych 
w okresie od 01.01.2009 do 1.01.2010 do dalszych badań zakwalifikowano 41 chorych, u których rozpoznano ogniskowe gromadzenie 
99mTc- sestamibi w tarczycy. Następnie przeprowadzono badanie kliniczne, wykonano USG tarczycy oraz oznaczono stężenie: TSH, fT4, 
fT3, aTPO, TRAb, kalcytoniny, CEA. Na podstawie wyniku badania ultrasonograficznego tarczycy 21 osób skierowano na biopsję cien-
koigłową tarczycy.
Wyniki: U 41 (12,4%) z 330 chorych poddanych scyntygrafii serca stwierdzono nieprawidłowe gromadzeniem radioznacznika w tarczycy. 
U 13 ( 31,7%) z nich rozpoznano wole wieloguzkowe, 12 (29,2%) miało pojedynczy guzek tarczycy ( w tym dwóch chorych guzek auto-
nomiczny), 11 chorych (26,8%) prezentowało autoimmunizacyjną chorobę tarczycy, u jednej (2,4%) znaleziono raka brodawkowatego 
tarczycy. W 12 przypadkach (29,2%) nieprawidłowego gromadzenia radioznacznika nie potwierdzono choroby tarczycy.
Wnioski: 
1. Dodatkowa ocena wychwytu radioznacznika w tarczycy podczas standardowej scyntygrafii perfuzyjnej serca jest cennym narzędziem 
w wykrywaniu chorób tarczycy. 
2. W opisie wyniku badania scyntygrafii perfuzyjnej serca powinno się także uwzględniać ocenę wychwytu radioznacznika w tarczycy. 
(Endokrynol Pol 2015; 66 (6): 521–525)
Słowa kluczowe: zmiany ogniskowe tarczycy; sestamibi; scyntygrafia serca; rak tarczycy; autoimmunologiczna choroba tarczycy
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with an activity of 740 MBq, was administered during 
either a treadmill stress test or a pharmacological test 
with dipyridamole. An Infinia Hawkeye 4 gamma 
camera (GE Healthcare, WI, USA) was used for imag-
ing with a low-energy, high-resolution collimator and 
64 × 64 camera matrix. Single-photon emission comput-
ed tomography (SPECT-CT) imaging was performed 
60 minutes after administration of the radiotracer. Image 
data were processed on a GE Xeleris diagnostic station 
using software with a Volumetrix for Hawkeye option. 
As the field of view of the gamma camera detector was 
54 × 40 cm, the “window” of the test before software 
processing (for heart examination) covered part or all 
of the thyroid gland.
SPECT imaging of the thyroid field was performed 
in transversal, frontal, and lateral projections. Focal 
uptake of sestamibi in the thyroid was defined as 
a thyroid nodule. Forty-one patients were diagnosed 
with focal radiotracer uptake in the thyroid gland, and 
they underwent the following laboratory tests: thyroid 
stimulating hormone (TSH), thyroxine (fT4), triiodothy-
ronine (fT3), thyroid peroxidase antibodies (aTPO) and 
TSH receptor (TRAB), calcitonin, carcinoembryonic an-
tigen (CEA), calcium and phosphorus, and ultrasound 
of the thyroid gland. AutoDELFIA packages (Perki-
nElmer Life and Analytical Sciences, Turku, Finland) 
were used to determine TSH, fT3, and fT4. Anti-TPO 
and anti-TRAB antibody levels were determined by 
quantitative radioimmunoassay (BRAHMS, Hennigs-
dorf, Germany), and calcitonin and CEA were assayed 
using CLIA immunochemiluminescence (LIAISON; Di-
aSorin, Stillwater, MN). Each patient underwent thyroid 
ultrasonography (USt) (Siemens Acuson x150, CA, USA, 
linear probe at 10 MHz frequency), and based on the 
results, 21 patients qualified for fine-needle aspiration 
according to Polish recommendations [2]. Selected cases 
were referred for thyroid resection. All of the patients 
were informed about the purpose and method of the 
examination, and they gave their written consent. The 
study protocol was approved by the Bioethics Com-
mittee of the Military Institute of Medicine in Warsaw.
Results
We analysed 330 myocardial perfusion images, and focal 
uptake was observed in 41 cases (12.4%). Among the 
41 patients enrolled in the next stage, 16 were men and 
25 were women. The mean age was 63.4 years (men, 
61.7; women, 64.9). Thyroid disease was confirmed in 
29 patients (70.7%) by ultrasound and/or laboratory 
tests. Eight of the patients were diagnosed with two 
thyroid pathologies. Each of the pathologies was con-
sidered as a separate case; thus, the number of patholo-
gies identified was 37.
Introduction
Myocardial perfusion scintigraphy is a valuable tool in 
the diagnosis of ischaemic heart disease. This test uses 
sestamibi labelled with 99mTc (99mTc-sestamibi), which ac-
cumulates in the cells and is characterised by enhanced 
metabolism, high proliferative activity, and increased 
number of mitochondria. These features are also typi-
cal of tumour cells [1]. For this reason, sestamibi is used 
in nonspecific cancer diagnostics, including breast, 
thyroid, and lung cancers [1]. Due to its high positive 
predictive value, sestamibi imaging is used in thyroidol-
ogy, to qualify lesions for cytological examination, while 
negative prediction helps in identifying thyroid nod-
ules, qualified based on a biopsy to Bethesda category 
III (follicular lesion of undetermined significance) and 
category IV (suspicious for a follicular neoplasm) [1, 
2]. Lack of uptake excludes, while increased uptake 
indicates, the malignant nature of the lesion [3].
Ultrasonography is more accessible and is used 
more commonly in the differential diagnosis of thyroid 
cytopathology. Scintigraphic imaging is associated with 
exposure to ionising radiation, and therefore, it is rarely 
used in the diagnosis of thyroid nodules. However, 
there is a large group of patients in whom sestamibi 
analysis is performed to assess myocardial perfusion 
in the diagnosis of coronary artery disease. While raw 
images (before software processing) obtained during 
this test comprise a “window” that may include part 
or all of the thyroid field, nuclear physicians who 
evaluate myocardial perfusion omit extracardiac image 
elements from further analysis. Nonetheless, additional 
evaluation of sestamibi uptake in the thyroid during 
myocardial perfusion scintigraphy might be a valuable 
tool in the diagnosis of thyroid disease, and it requires 
no additional monetary expenditure or exposure to 
additional ionising radiation. Evaluation of the thyroid 
during myocardial scintigraphy can also be consid-
ered a screening test with high positive prediction of 
malignancy, reaching more than 20% according to some 
sources [3, 4]. 
The aim of this study was to analyse the usefulness 
of additional assessment of the thyroid gland during 
stress scintigraphy using sestamibi in order to detect 
thyroid pathology and evaluate thyroid function.
Material and methods
We retrospectively evaluated 330 consecutive myo-
cardial perfusion images captured in the Department 
of Nuclear Medicine, Military Institute of Medicine in 
Warsaw, from 14 January 2009 to 6 December 2009. The 
tests had been conducted for the diagnosis or control of 
coronary disease. The radiopharmaceutical sestamibi, 
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Thyroid nodules were observed in 25 patients in the 
study group (n = 41; 60.9%) [Table 1], including 13 cases 
of multinodular lesions (31.7%), and 12 cases of single 
nodules (29.2%). Among the single changes, two cases 
of autonomous nodules in the subclinical hyperthyroid-
ism stage were found. Ten patients were diagnosed with 
Hashimoto`s thyroiditis (AT autoimmune thyroiditis) 
based on elevated levels of anti-TPO antibodies and the 
characteristic ultrasound image; two of those patients 
had elevated TSH levels and clinical hypothyroidism 
features. These cases represented 24.4% of the study 
group. One subject was diagnosed with Graves’ disease 
with clinical and hormonal euthyroid. Together, autoim-
mune diseases were found in 26.8% of the study group. 
In 12 patients (29.2%) with thyroid radiotracer uptake 
there was no thyroid pathology. The values of CEA and 
calcitonin were normal in all patients.
Fine-needle aspiration biopsy of the thyroid, accord-
ing to the guidelines of the Polish Thyroid Association, 
was performed in 21 patients [2]. One case of papillary 
thyroid carcinoma was determined and confirmed by 
histopathology after thyroidectomy: pT1b(m)N1Mx.
Discussion
The results of autopsies indicated that approximately 
50% of the population had thyroid nodules [5] and 36% 
had thyroid cancer [6]. According to the 2009 data of the 
Central Statistical Office, 4.6% of the Polish population 
was diagnosed with thyroid disease [7]. The almost 
ten-fold disparity in prevalence rate between autopsy 
results and clinical studies highlights the importance 
of searching for new thyroid diagnostic methods or 
modifying the existing ones.
Extensive screening and the subsequent diagnostics 
of thyroid nodules would result in huge costs from 
public funds. In addition, such an undertaking would 
not provide certainty in cancer exclusion, as most cases 
involve multinodular goitres, and separate diagnos-
tics of each lesion is usually impossible. The situation 
changes with the application of high positive prediction 
tests performed for non-thyroidal indications. Such 
screening tests do not generate additional costs, and the 
selected cases represent a high-risk group that require 
further diagnostics. Myocardial perfusion scintigraphy, 
evaluated in the current study, certainly belongs in that 
category of procedures.
Ever since 99mTc-sestamibi was synthesised for the 
first time (1982), many studies have been carried out 
to assess the usefulness of the radiopharmaceutical in 
cancer diagnostics. Benign lesions are characterised by 
the lack of accumulation of the radiopharmaceutical. 
Hurtado-Lopez et al. [4] evaluated nine studies involv-
ing 448 patients with hypofunctional thyroid nodules, 
who underwent sestamibi imaging. Uptake of the 
radiopharmaceutical was detected in all 127 cases of 
differentiated and four medullary thyroid carcinomas 
and in one of three anaplastic carcinoma cases. Based on 
this analysis, it was concluded that a lack of uptake of 
sestamibi in thyroid nodules precludes the existence of 
differentiated thyroid cancer. Approximately two-thirds 
(i.e. 212 patients) of the benign thyroid nodule cases 
were characterised by an accumulation of sestamibi. 
Therefore, the positive prediction rate of malignancy 
in the study group was 38.2%. We did not expect such 
results, for several reasons. First, the qualification for 
inclusion in the group was based on abnormal sesta-
mibi uptake in the thyroid, and not thyroid nodules 
detected by ultrasound. As such, there was a group 
with no thyroid pathology (12 patients), and thyroid 
nodules confirmed by USt occurred in 25 patients (61%). 
In addition, by treating myocardial perfusion scintig-
raphy as a screening test, we had no previous data on 
thyroid diseases in these patients. It should be noted 
that the cited work qualified patients diagnosed with 
thyroid nodules, while “warm” and “hot” changes in 
the iodine or technetium scintigraphy were excluded. 
Thus, in the study group, one case of differentiated 
Table I. Summary of the results
Tabela I. Podsumowanie wyników
Diagnosis n %
No thyroid pathology 12 29.2%
Thyroid nodules Single nodules Autonomus nodule 2 4.9%
29.2%
61%
Other 10 24.4%
Multinodular goitre 13 31.7%
Thyroid cancer 1 2.4%
Autoimmune thyroid disorders AT 10 24,4%
Graves' disease 1 2.4%
AT — autoimmune thyroiditis (Hashimoto's Thyroiditis)
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thyroid cancer was found out of 41 patients showing 
sestamibi uptake (2.4%).
Not without significance is the method of the study. 
Sestamibi imaging has previously been performed in 
many ways. Kresnik et al. [8] evaluated the washout of 
the radiopharmaceutical by two-phase scanning per-
formed 30 and 120 minutes after injection. The result 
was an 84% negative prediction, not 100%. Hurtado-
Lopez et al. [3] used a combination of pertechnetate and 
sestamibi scans. The technetium test allowed them to 
separate patients with hypofunctional nodules, who 
subsequently underwent sestamibi imaging. Nodules 
that did not uptake any of the tracers (so-called match-
es) were always benign. In contrast, nodules “cold” in 
technetium scintigraphy and “hot” using sestamibi 
(so-called mismatches) were characterised by a posi-
tive malignancy prediction of 60.9%. The setup of our 
study was different; the tracer was injected during the 
stress test or after the administration of dipyridamole, 
and imaging was performed once after 60 minutes. 
We did not find any studies in the literature similar to 
our method. Provided that our study was a screening 
examination to assess the thyroid function of patients 
undergoing myocardial perfusion imaging, adjusting 
the diagnostic scheme would change the aim of the 
study. Thyroid nodules were found to be present in 61% 
of our study group, which is higher than the incidence 
rate in the general population, estimated at 50% based 
on autopsies [5].   
Many studies have been performed to demonstrate 
the usefulness of further diagnostics of thyroid inciden-
talomas. Czepczyński et al. [9], who analysed thyroid 
nodules found accidentally during positron emission 
tomography CT (PET-CT) with 18F-FDG, adopted as-
sumptions similar to ours. The authors evaluated 1925 
PET-CT scans performed to diagnose and determine 
the severity of cancers with extrathyroidal starting 
points. They found thyroid incidentalomas in 71 cases 
(3.7%), of which six were papillary carcinomas, one 
was a medullary carcinoma, and one was a case of lung 
cancer metastasis to thyroid. The positive prediction 
rate of malignant incidentalomas in their study was 
high at 40%. The incidence rate of thyroid inciden-
taloma found during myocardial perfusion imaging in 
our study was 18.4%, but the specificity in malignant 
tumour diagnostics was significantly lower. One of the 
reasons might be the lack of determination of cutoff 
points characteristic of malignancy in clinical SPECT-
CT, which increases the frequency of lesion detection 
and decreases specificity, largely dependent on the 
experience of the diagnostician. PET studies use stand-
ardised uptake values, which allow a high certainty of 
determination of malignancy risk.
Assessment of the usefulness of sestamibi scintig-
raphy for the detection of autoimmune thyroid dis-
eases is a separate issue. Santos et al. [10] attempted 
to determine the optimal time interval between 
administration of the radiotracer and maximum 
uptake in the organ to obtain the best quality in the 
diagnostics of autoimmune thyroid diseases. They 
studied healthy patients with atrophic and hyper-
trophic Hashimoto’s thyroiditis and Graves’ disease 
and found that a five-minute interval between 
administration of the tracer and the measurement 
was optimal. Using that interval, they were able 
to distinguish healthy patients from subjects with 
autoimmune thyroid disease, with the exception of 
an atrophic form in which sestamibi accumulation 
was lower than in healthy subjects. Although imag-
ing was performed 60 minutes after administration 
of the radiotracer in our study, we found ten cases 
of chronic autoimmune thyroiditis and one case of 
Graves’ disease, for a total of 26.8%. The ratio of male 
to female was five to six, and the estimated incidence 
rate of autoimmune thyroid disease in the population 
was 4–10% [11]. 
In 12 patients (29.2%) with focal uptake of ses-
tamibi we did not find any thyroid pathology. We 
suppose that this finding is due to the contamination 
of sestamibi with free technetium during production 
of radiotracer. 
We do not find any studies in the medical literature 
pertaining to the issue discussed in our work. The 
results of this study indicate the need for a broader 
perspective on myocardial perfusion scintigraphy. Most 
thyroid diseases that can be diagnosed during the test 
are in the presymptomatic phase. Early diagnosis and 
No thyroid pathology
Thyroid nodules
Autoimmune thyroiditis
Papillary thyroid cancer
Graves' disease
Figure 1. Patients with focal uptake in the thyroid qualified to 
the group (n = 41)
Rycina 1. Pacjenci z ogniskowym wychwytem sestamibi 
w tarczycy (n = 41)
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treatment improves the prognosis of thyroid cancers, 
while in benign diseases, early treatment can prevent 
extrathyroidal complications (heart, bones). 
By detecting additional autonomous nodule or pr-
esymptomatic forms of Graves’ disease, we can prevent 
symptomatic hyperthyroidism after iodine load during 
the next diagnostic stage of coronary heart disease, 
which is coronary angiography. 
An important conclusion of this study is to consider 
sestamibi imaging in the detection of other cancers, 
such as lymphoma, breast, lung, and liver cancers. This 
costless, low-burden study should provide significant 
benefits in those cases as well. 
Conclusions
1. Additional evaluation of radiotracer uptake in the 
thyroid during standard myocardial perfusion 
scintigraphy is a valuable tool in the detection of 
thyroid diseases. 
2. The additional or parallel evaluation of radiotracer 
uptake in the thyroid should be considered during 
every myocardial scintigraphy.
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